Cognition Therapeutics Inc. (NASDAQ: CGTX)
$1.96
+0.0400 ( +2.08% ) 62.3K
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Market Data
Open
$1.96
Previous close
$1.92
Volume
62.3K
Market cap
$79.32M
Day range
$1.90 - $2.02
52 week range
$0.90 - $2.95
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Feb 20, 2024 |
4 | Insider transactions | 1 | Feb 09, 2024 |
4 | Insider transactions | 1 | Feb 09, 2024 |
8-k | 8K-related | 50 | Jan 04, 2024 |
3 | Insider transactions | 1 | Nov 13, 2023 |
4 | Insider transactions | 1 | Nov 13, 2023 |
4 | Insider transactions | 1 | Nov 13, 2023 |
8-k | 8K-related | 14 | Nov 02, 2023 |
10-q | Quarterly Reports | 55 | Nov 02, 2023 |
8-k | 8K-related | 36 | Sep 12, 2023 |